Patents by Inventor Scott L. Harbeson

Scott L. Harbeson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190308976
    Abstract: The present invention in one embodiment provides a compound of Formula A: or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising the compound; and methods of treating the indications disclosed herein.
    Type: Application
    Filed: March 11, 2019
    Publication date: October 10, 2019
    Inventors: I. Robert Silverman, Julie F. Liu, Adam J. Morgan, Bhaumik Pandya, Scott L. Harbeson
  • Patent number: 10385042
    Abstract: This invention relates to novel inhibitors of UDP-glucose: N-acyl-sphingosine glucosyltransferase and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering inhibitors of UDP-glucose: N-acyl-sphingosine glucosyltransferase.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: August 20, 2019
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Scott L. Harbeson
  • Patent number: 10357499
    Abstract: This invention relates to novel substituted triazolobenzodiazepines of the Formula I: wherein each of the variables are defined herein and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering I-BET762.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: July 23, 2019
    Assignee: Concert Pharmaceutical, Inc.
    Inventor: Scott L. Harbeson
  • Patent number: 10335413
    Abstract: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: July 2, 2019
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Roger D. Tung, Julie F. Liu, Scott L. Harbeson
  • Publication number: 20180333417
    Abstract: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.
    Type: Application
    Filed: March 15, 2018
    Publication date: November 22, 2018
    Inventors: Roger D. Tung, Julie F. Liu, Scott L. Harbeson
  • Publication number: 20180303848
    Abstract: This invention relates to novel substituted triazolobenzodiazepines of the Formula I: wherein each of the variables are defined herein and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering I-BET762.
    Type: Application
    Filed: July 2, 2018
    Publication date: October 25, 2018
    Applicant: Concert Pharmaceuticals, Inc.
    Inventor: Scott L. Harbeson
  • Publication number: 20180298028
    Abstract: This invention relates to novel thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepines, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of binding between an acetylated histone and a bromodomain-containing protein.
    Type: Application
    Filed: October 27, 2016
    Publication date: October 18, 2018
    Inventors: Scott L. Harbeson, Julie F. Liu
  • Patent number: 10039769
    Abstract: This invention relates to novel substituted triazolobenzodiazepines of the Formula I: wherein each of the variables are defined herein and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering I-BET762.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: August 7, 2018
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Scott L. Harbeson
  • Patent number: 9944635
    Abstract: This invention in one embodiment is directed to a compound of Formula Ia; where the designation (R) indicates that the designated carbon has the (R) stereochemistry; and wherein Z1 is hydrogen or fluorine; Z2 is hydrogen, deuterium, or fluorine; Z3 is deuterium; Z4 is fluorine; m is an integer from 0 to 10; n is an integer from 0 to 2; provided that: the sum of m+n does not exceed 10; and when both Z1 and Z2 are hydrogen, the sum of m+n is greater than 0, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an antihelminthic agent, such as praziquantel.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: April 17, 2018
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Julie F. Liu, Scott L. Harbeson, Roger D. Tung
  • Publication number: 20180086743
    Abstract: This invention relates to novel inhibitors of UDP-glucose: N-acyl-sphingosine glucosyltransferase and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering inhibitors of UDP-glucose: N-acyl-sphingosine glucosyltransferase.
    Type: Application
    Filed: September 11, 2017
    Publication date: March 29, 2018
    Applicant: Concert Pharmaceuticals, Inc.
    Inventor: Scott L. Harbeson
  • Patent number: 9918987
    Abstract: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: March 20, 2018
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Roger D. Tung, Julie F. Liu, Scott L. Harbeson
  • Publication number: 20180044375
    Abstract: This invention relates to novel 3-amido-4-oxo-5-phenoxypentanoic acids, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a caspase protease inhibitor.
    Type: Application
    Filed: March 4, 2016
    Publication date: February 15, 2018
    Inventor: Scott L. Harbeson
  • Patent number: 9783528
    Abstract: This invention relates to novel inhibitors of UDP-glucose: N-acyl-sphingosine glucosyltransferase and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering inhibitors of UDP-glucose: N-acyl-sphingosine glucosyltransferase.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: October 10, 2017
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Scott L. Harbeson
  • Publication number: 20170258807
    Abstract: This invention relates to novel substituted triazolobenzodiazepines of the Formula I: wherein each of the variables are defined herein and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering I-BET762.
    Type: Application
    Filed: May 31, 2017
    Publication date: September 14, 2017
    Applicant: Concert Pharmaceuticals, Inc.
    Inventor: Scott L. Harbeson
  • Publication number: 20170239254
    Abstract: The present invention in one embodiment provides a compound of Formula A: or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising the compound; and methods of treating the indications disclosed herein.
    Type: Application
    Filed: March 9, 2017
    Publication date: August 24, 2017
    Inventors: I. Robert Silverman, Julie F. Liu, Adam J. Morgan, Bhaumik Pandya, Scott L. Harbeson
  • Patent number: 9694017
    Abstract: This invention relates to novel substituted triazolobenzodiazepines of the Formula (I), wherein each of the variables are defined herein and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering I-BET762.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: July 4, 2017
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Scott L. Harbeson
  • Patent number: 9676790
    Abstract: The present invention in one embodiment provides a compound of Formula I: (I), or a pharmaceutically acceptable salt thereof, wherein Y1, Y2 and Y3 are each independently selected from hydrogen and deuterium; R1, R2, and R3 are each methyl and are independently substituted with 0 to 3 deuterium; and R4 is t-butyl and is substituted with 0 to 9 deuterium; provided that if R1, R2 and R3 are each —CH3, and R4 is —C(CH3)3, then at least one of Y1 and Y2 is deuterium.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: June 13, 2017
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Scott L. Harbeson
  • Publication number: 20170027946
    Abstract: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.
    Type: Application
    Filed: October 12, 2016
    Publication date: February 2, 2017
    Inventors: Roger D. Tung, Julie F. Liu, Scott L. Harbeson
  • Publication number: 20160346296
    Abstract: This invention relates to novel substituted triazolobenzodiazepines of the Formula (I), wherein each of the variables are defined herein and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering I-BET762.
    Type: Application
    Filed: February 9, 2015
    Publication date: December 1, 2016
    Inventor: Scott L. Harbeson
  • Patent number: 9493463
    Abstract: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: November 15, 2016
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Roger D. Tung, Julie F. Liu, Scott L. Harbeson